Therapeutic areas graphic
+1000 sites
in 50+ countries have conducted feasibility assessments for MS studies

Multiple Sclerosis Phase II & III Clinical Trials

Consistent on-time and on-budget delivery on dozens of MS trials, current contact templates with hundreds of institutions, expert knowledge of specifics of running placebo-controlled MS trials around the world, and more...

Excellent relationships and MSAs with productive sites around the world.
FDA and EMA inspections of PSI's MS sites resulting in drug approval.

Feasibility

PSI is an expert at conducting regional or global feasibility that provides the best choice of sites and geography with accurate recruitment forecasts.

In recent years, our specialists located in 11 countries of North America, Europe, Asia and Latin America have conducted feasibility assessments for Multiple Sclerosis studies in 50+ countries at 1000+ sites. These assessments cover, but are not restricted to, evaluation of the target population availability and factors that limit it, standards of care, competitive studies, regulatory climates and the need to engage particular Key Opinion Leaders into the study. We weigh all of these factors before making recommendations on the best choice of sites and geography for your program. 

Patient Populations:

  • Relapse-Remitting Multiple Sclerosis (RRMS)
  • Secondary Progressive Multiple Sclerosis (SPMS)
  • Relapsing Multiple Sclerosis (RMS)
  • Adult and pediatric populations

Experience in:

  • Active-controlled & placebo-controlled designs
  • Bioequivalent trials
  • Programs of several studies

MS Agents:

     DMDs

  • Interferons
  • Glatiramer acetate
  • Monoclonal antibodies
  • Immunomodulating drugs
  • IV immunoglobulins

     Symptomatic treatment:

  • Spasticity

MS is a competitive indication and good sites have ample choices about which studies to put patients on and which to keep on a back-burner. 

Research shows that how sites percieve CROs influences how they percieve the sponsor. According to the global bi-annual investigator survey run by CenterWatch, PSI was voted number 1 CRO in the majority of categories in both 2015 and 2017. Heavy investment into site relations and management are a function of successful patient enrollment that PSI sees across MS sites around the world.

 

Meet the global clinical research organization ranked No. 1.

“PSI is an excellent company. These people know their clients and their resources, anticipate problems and propose solutions before you even realize you need them.” Client CEO

The PSI Advantage

Ranked #1 Global CRO by Investigators Worldwide

Ranked #1 Global CRO by Investigators
Worldwide. CenterWatch 2015-2017

Therapeutic areas

Other therapeutic areas of expertise